View in EDS

Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck.

Saved in:
Bibliographic Details
Title: Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck.
Authors: Beyaert S; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium. simon.beyaert@saintluc.uclouvain.be., Loriot A; Group of Computational Biology and Bioinformatics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium., Magremanne M; Department of Oral and Maxillofacial surgery, Institut Roi Albert II & Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Renwart W; Department of Head & Neck Surgery, Institut Roi Albert II & Cliniques universitaires Saint-Luc, Brussels, Belgium., Mahy P; Department of Oral and Maxillofacial surgery, Institut Roi Albert II & Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Duprez T; Department of Radiology, Institut Roi Albert II & Cliniques universitaires Saint-Luc, Brussels, Belgium., Baldin P; Department of Pathology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Benidovskaya E; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Huyghe N; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Dahou H; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Stroobant V; de Duve Institute, Ludwig Institute for Cancer Research, Brussels, Belgium., Gomard T; de Duve Institute, Ludwig Institute for Cancer Research, Brussels, Belgium., Machiels JP; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Department of Medical Oncology, Institut Roi Albert II & Cliniques universitaires Saint- Luc, Brussels, Belgium., Schmitz S; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Department of Head & Neck Surgery, Institut Roi Albert II & Cliniques universitaires Saint-Luc, Brussels, Belgium.
Source: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2025 Nov; Vol. 282 (11), pp. 5841-5855. Date of Electronic Publication: 2025 Sep 03.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Springer International Country of Publication: Germany NLM ID: 9002937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1434-4726 (Electronic) Linking ISSN: 09374477 NLM ISO Abbreviation: Eur Arch Otorhinolaryngol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1434-4726
DOI:10.1007/s00405-025-09655-8